Abstract
In recent years there has been a significant improvement in the outcome of children with standard risk acute myelogenous leukemia (AML) treated with chemotherapy only. In the MRC-UK trials 10 and 12, standard risk AML children were allowed to proceed to hematopoietic stem cell transplantation (HSCT) if there is a full matched family donor. However, with the excellent results of chemotherapy and the known risks and long term effects of HSCT, this decision remains controversial. Herein, our objective was to review the outcome of all children between 1995-2005 with standard risk AML who received a matched sibling donor (MSD) in CR1 in our institution and compare their outcome with the published MRC-UK results.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
